Clinical Guides
National Immunisation Schedule in India
A clinically focused guide to India’s public immunisation schedule, 2026 HPV addition, delayed-dose recovery and safe programme delivery, prepared for mandatory clinical review.
MedNext Academy | 12 min read
National Immunisation Schedule in India
A clinically focused guide to India’s public immunisation schedule, 2026 HPV addition, delayed-dose recovery and safe programme delivery, prepared for mandatory clinical review.
Summary
India’s National Immunisation Schedule is a public-programme timetable, not a complete private-sector schedule for every age and risk group. The core sequence begins with BCG, oral polio vaccine zero dose and hepatitis B birth dose; continues at 6, 10 and 14 weeks with oral polio, pentavalent and rotavirus vaccines plus age-specific fractional IPV and pneumococcal conjugate doses; adds MR, PCV booster, fractional IPV and endemic-district JE at 9-12 months; provides second-year MR, DPT, OPV and endemic-district JE boosters; and continues with DPT at 5-6 years and Td at 10 and 16 years. Pregnant women receive Td according to previous vaccination. In February 2026, India launched free single-dose quadrivalent HPV vaccination for eligible 14-year-old girls, initially through a nationwide campaign and subsequently on routine immunisation days at designated government facilities. A missed appointment normally triggers catch-up, not restarting a completed series, but the product, minimum interval, upper age limit and current MoHFW or state circular must be checked. Administer all due compatible vaccines in one visit at separate sites when permitted. Screen for true contraindications, maintain cold chain, prevent administration errors, record in the home-based card and U-WIN or programme register, and keep an in-date anaphylaxis kit. This educational draft requires MedNext Clinical Team review before release.
How Common Is It?
Routine immunisation is one of India’s largest recurring health-service activities, reaching pregnant women, newborns, infants, children and adolescents through fixed facilities, outreach sessions and campaigns. Coverage is not uniform: national averages can conceal zero-dose children, delayed doses, missed urban migrants, remote tribal communities, conflict or disaster interruptions and differences between districts. MoHFW reported national full-immunisation coverage above 90% for four consecutive financial years, including 97.9% for 2025-26, but this programme indicator should not be interpreted as proof that every antigen, booster, district or population subgroup achieved equivalent coverage. In February 2026 the HPV programme targeted roughly 1.15-1.2 crore girls aged 14 years across all states and union territories; by July the government continued to describe it as a nationwide initiative. The denominator and definition matter: ‘full immunisation’ generally concerns specified infant doses by a defined age, while ‘complete immunisation’, booster coverage, timely birth dosing and adolescent vaccination measure different gaps. A child can therefore be counted in one aggregate while still being late for another dose. At the bedside, population coverage never answers an individual eligibility question. Verify the beneficiary’s card, U-WIN record and credible prior documentation, reconstruct dates and products, then compare them with the current national and local schedule.
Risk Factors
The principal clinical risk is remaining susceptible because vaccination was never started, was delayed or stopped after a false contraindication. Access barriers include migration, nomadic work, seasonal flooding, distance, inconvenient session timing, vaccine stock-outs, absent home-based records and fragmented care between public and private providers. Prematurity and malnutrition are sometimes wrongly treated as reasons to defer routine vaccines; these children often need timely protection. Mild fever, simple upper-respiratory symptoms, diarrhoea without severe illness, breastfeeding, antibiotic use and family history of an adverse event are usually not blanket contraindications. True precautions are vaccine-specific. Do not repeat a product after anaphylaxis to that dose or a known component without expert assessment. Live vaccines require particular review in severe immunodeficiency and pregnancy. Moderate or severe acute illness may justify deferral until recovery, whereas urgency can outweigh minor symptoms during an outbreak. Programme risk also arises from wrong age, product, diluent, route, site or interval; freezing a freeze-sensitive vaccine; using a reconstituted vial beyond its permitted session; pre-filling syringes; or failing to record a dose. For the 2026 HPV programme, eligibility is 14-year-old girls with consent; government information excludes pregnancy, moderate or severe current illness, relevant severe allergy, girls outside the target age and those already given any HPV vaccine. Confirm current instructions because campaign boundaries and supply policy can change.
Diagnosis
History
Immunisation assessment begins by identifying the beneficiary, date of birth or gestational context, residence, pregnancy status and reason for attendance. Review the physical card, U-WIN or facility register and reliable private records. List each antigen, product, date, dose number and any reaction. Ask about previous anaphylaxis, severe immunodeficiency, immunosuppressive treatment, blood products, pregnancy and current illness. Clarify migration, missed sessions and whether an undocumented claim can be verified; do not assume that a scar proves a complete schedule.
Examination
A routine pre-vaccination physical examination need not become an unnecessary screening battery. Assess general condition, temperature when clinically indicated, hydration, respiratory distress and evidence of moderate or severe acute illness. Check the intended injection sites and confirm age-appropriate positioning. In pregnancy, verify the antenatal context. For HPV, confirm the programme age and exclusions. A well child with a minor illness usually remains eligible.
Investigations
Routine antibody testing, full blood count or imaging is not required before scheduled vaccination. Laboratory evaluation belongs to a defined clinical problem, such as suspected immunodeficiency or uncertain hepatitis B immunity in a special-risk pathway. The essential ‘investigation’ is record reconciliation: calculate age on the session date, determine valid prior doses and minimum intervals, consult the current MoHFW/state catch-up table and document the decision. After vaccination, observe per programme instructions and investigate serious or severe AEFI through the national process rather than assuming causation.
Differential Diagnosis
A schedule discrepancy is not always true non-vaccination. Distinguish a missing paper card from a genuinely absent dose by checking U-WIN, previous facility registers and credible private documentation. Separate a dose given late but valid from one given too early, at the wrong interval, by the wrong route or with compromised stock; programme guidance determines whether an invalid dose must be repeated. Differentiate the Universal Immunisation Programme schedule from Indian Academy of Pediatrics or other private recommendations: additional vaccines may be clinically appropriate, but they are not automatically supplied under UIP and must not be displayed as national entitlements. Campaign doses can supplement rather than replace routine doses, depending on the antigen and campaign rules. A BCG scar may be absent after successful vaccination and is not by itself a reason for automatic revaccination. Fever or local soreness after a vaccine is different from an AEFI requiring urgent evaluation; anaphylaxis, encephalopathy, hospitalisation, clustering or any event causing community concern requires structured assessment and reporting. Immunisation stress-related responses, syncope and anxiety may mimic allergic reactions. Finally, distinguish contraindication from precaution: a prior mild fever is not an allergy, while documented anaphylaxis to a component requires specialist planning. The practical output is an antigen-by-antigen eligibility list, not the broad label ‘fully vaccinated’ or ‘unvaccinated’ without dates.
Management
At every contact, reconcile the record and give all vaccines currently due and permitted, using separate anatomical sites and syringes. Do not restart a primary series merely because the interval became long; continue with the next valid dose while observing national minimum intervals, product age limits and state instructions. The core schedule is: birth—BCG, OPV-0 and hepatitis B within 24 hours; 6 weeks—OPV-1, pentavalent-1, rotavirus-1, fIPV-1 and PCV-1; 10 weeks—OPV-2, pentavalent-2 and rotavirus-2; 14 weeks—OPV-3, pentavalent-3, rotavirus-3, fIPV-2 and PCV-2; 9-12 months—MR-1, PCV booster, fIPV-3 and JE-1 only in designated endemic districts; 16-24 months—MR-2, DPT booster-1, OPV booster and endemic-district JE-2; 5-6 years—DPT booster-2; 10 and 16 years—Td. Vitamin A accompanies programme contacts under its separate supplementation schedule. Pregnancy: give Td-1 early and Td-2 at least four weeks later, or one Td booster when two valid doses were documented during a pregnancy within the previous three years. Eligible 14-year-old girls receive one Gardasil-4 dose through the 2026 national HPV programme after consent. For catch-up, never improvise an adult private schedule from this table; consult the current antigen-specific government chart, particularly upper-age limits for BCG, rotavirus, pentavalent, MR, JE, PCV and fractional IPV. Keep every recipient at the session site for at least 30 minutes. If anaphylaxis is suspected, the trained vaccinator gives one immediate age-appropriate IM dose of adrenaline 1 mg/mL—0.01 mL/kg, capped at 0.5 mL—then transfers to an AEFI management centre; the medical officer reassesses ABC, repeats treatment if required and observes the recovered patient for at least 12-24 hours under the national pathway. Book the next vaccine date, record it and actively link migrants or defaulters to the nearest session.
Prescribing Information
The correct dose, route, site, presentation and diluent are product- and programme-specific. Under routine UIP practice, BCG is intradermal in the left upper arm: 0.05 mL through one month of age and 0.1 mL thereafter when still eligible; OPV is two oral drops; hepatitis B birth dose and pentavalent are 0.5 mL intramuscular injections in the anterolateral thigh; fractional IPV is 0.1 mL intradermally in the right upper arm; PCV is 0.5 mL intramuscularly; MR and the commonly used live JE presentation are administered subcutaneously at designated upper-arm sites; DPT and Td are 0.5 mL intramuscularly. Rotavirus volume differs by supplied product, so read the vial and current job aid rather than memorising one volume. Never substitute a diluent, combine products in one syringe or pre-fill doses for later recipients. Check vaccine vial monitor, expiry, label, appearance, open-vial eligibility and cold-chain history. Reconstituted BCG, MR and relevant JE products have limited session life and require disposal under current guidance. Give oral vaccines before injections when practical and use age-appropriate needle and site. Document batch, dose, route, site, date and vaccinator. Maintain adrenaline 1 mg/mL and a complete anaphylaxis kit at every session. For Gardasil-4 in the 2026 national programme, use the government-supplied single-dose pathway for eligible 14-year-old girls; a private HPV product or multidose history requires reconciliation rather than automatic additional programme dosing.
When to Refer
Most routine beneficiaries can be vaccinated at a trained primary-care or outreach session, but refer before selecting a product when there is previous anaphylaxis to a vaccine or component, suspected severe immunodeficiency, current chemotherapy or high-dose immunosuppression, organ or stem-cell transplantation, complex asplenia, uncertain live-vaccine safety, or an adverse event that may change future doses. Premature infants generally follow chronological age, yet very low birth weight, ongoing instability or prolonged admission may require neonatal and paediatric coordination. Seek obstetric advice when vaccination outside routine pregnancy Td is being considered. A child with moderate or severe acute illness should be clinically assessed and vaccinated once safe, with a documented return plan rather than indefinite deferral. Urgently transfer any post-vaccination anaphylaxis, shock, respiratory compromise, prolonged seizure, encephalopathy or other severe event, administer immediate authorised care and notify the medical officer. Serious, severe, clustered or publicly concerning AEFI enters the district/state reporting and investigation pathway. Refer an uncertain catch-up history to an immunisation clinic or paediatrician when product age limits and minimum intervals cannot be resolved locally. For refugees, international travellers, animal-bite prophylaxis, occupational exposure and adult high-risk vaccination, use the relevant dedicated guideline; the childhood UIP table alone is insufficient. Good referral includes the card or record extract, products and batch numbers, dates, reaction chronology and a precise clinical question.
Red Flags
Never miss the time-sensitive birth dose of hepatitis B: administer as soon as possible within 24 hours according to the programme, while arranging appropriate management for an infant born to a mother with hepatitis B under the applicable perinatal protocol. A child with no vaccines, multiple missed antigens or exposure during an outbreak needs same-day programme review, not a generic future appointment. Red flags before administration include an illegible label, expired vial, failed vaccine vial monitor, frozen freeze-sensitive stock, wrong or unavailable diluent, uncertain reconstitution time, damaged cold chain, absent emergency kit or inability to identify the recipient. Stop and correct the system rather than ‘using up’ stock. After vaccination, respiratory difficulty, stridor, generalised urticaria with physiological compromise, hypotension, collapse, persistent altered consciousness, prolonged seizure or rapid deterioration requires emergency management and AEFI notification. Do not dismiss an event because the vaccine is usually safe, and do not state that temporal association proves causation. Programme red flags include repeated dropout between first and third infant doses, geographic clusters of zero-dose children, stock-outs, missed outreach sessions, recording discrepancies and doses entered without administration. For the HPV programme, vaccination without valid consent, outside the defined target group, during pregnancy, after relevant anaphylaxis, or despite already documented HPV vaccination conflicts with current national eligibility information and requires correction.
Indian Clinical Context
UIP provides vaccines free of cost through government services, but the applicable schedule is a living national programme supported by state and district microplans, stock availability, endemicity and new-vaccine circulars. JE is limited to designated endemic districts. PCV and other products that entered in phases should now be checked against current local supply rather than historical footnotes. U-WIN strengthens beneficiary registration and dose records, yet the home-based Mother and Child Protection card remains important for families moving between facilities. A clinician should reconcile both and correct duplicates without deleting valid history. The 2026 HPV launch materially changes older schedule posters: eligible girls aged 14 years receive one free Gardasil-4 dose after consent at designated government facilities, and official communication states that routine-day availability follows the initial campaign. Do not silently graft private paediatric vaccines, travel vaccines or adult occupational recommendations onto UIP. Explain which doses are national entitlements, which depend on endemic area or campaign eligibility, and which require an individual private or special-risk assessment. Stock discipline is clinical safety: forecast sessions, monitor cold-chain equipment and vaccine vial monitors, segregate look-alike products, use correct diluents, avoid avoidable wastage while obeying open-vial rules, and never compromise safety to meet a target. Missed-dose recovery should be proactive through line lists, ASHA/ANM outreach and documented appointments. AEFI readiness, transparent communication and prompt reporting sustain trust better than promising that no reaction can occur.
NMC Competency Mapping
This guide maps chiefly to Community Medicine competencies in the Universal Immunisation Programme, national health programmes, cold chain, vaccine logistics, safe injection, communication, surveillance and AEFI response. It also integrates Paediatrics for age-based clinical assessment and catch-up, Obstetrics for maternal Td, Microbiology for live, inactivated, toxoid and conjugate vaccine principles, and Pharmacology for dose, route, adverse reactions and contraindications. A competent learner should reconstruct the national schedule from birth through adolescence; identify district-limited JE and the 2026 single-dose HPV addition; distinguish full from complete immunisation; calculate which dose is due from an actual dated record; avoid restarting a delayed series; and explain why private recommendations are not identical to UIP. Demonstrated skills should include checking a vial label, expiry and vaccine vial monitor; selecting route and site; counselling a caregiver; documenting in the card and digital register; preparing an anaphylaxis response; and notifying a serious AEFI without asserting causality. Public-health reasoning includes locating dropout points, planning catch-up, protecting migrants and using coverage data without hiding local inequity. Exact competency numbers must be verified against the institution’s adopted NMC CBME edition and logbook before publication. Assessment is strongest when learners solve records and session failures, not merely recite an age table.
Key Exam Pearls for NEET PG
Birth vaccines are BCG, OPV-0 and hepatitis B; the hepatitis B birth dose is time-critical within 24 hours. The 6-10-14-week backbone is OPV, pentavalent and rotavirus, with fIPV at 6 and 14 weeks and PCV at 6 and 14 weeks. The 9-12-month contact brings MR-1, PCV booster, fIPV-3 and JE-1 in endemic districts. At 16-24 months remember MR-2, OPV booster, DPT booster-1 and endemic-district JE-2. DPT booster-2 is at 5-6 years; Td is scheduled at 10 and 16 years. Pregnancy uses Td-1, Td-2 or a recent-course booster according to documented history. India’s February 2026 programme adds a voluntary, consented, free single Gardasil-4 dose for eligible 14-year-old girls. A delayed series is generally continued, not restarted, but each antigen’s permitted age and minimum interval must be checked. Multiple eligible vaccines can usually be given at one visit at different sites. BCG and fIPV are intradermal; OPV and rotavirus are oral; pentavalent, hepatitis B, PCV, DPT and Td are intramuscular; MR and relevant JE presentations use the programme-specified subcutaneous route. AEFI is an event after immunisation, not proof of causation. Every session needs correct cold chain, anaphylaxis kit, documentation and referral linkage.
Frequently Asked Questions
Should an infant restart all vaccines after missing several scheduled visits?
Usually no. Valid previous doses continue to count, and the child should receive currently due vaccines using the current Indian catch-up instructions, age limits and minimum intervals. Reconstruct the dated record, administer compatible doses at separate sites, document them, and book the next visit instead of restarting automatically.
Is the Indian private paediatric vaccine schedule identical to the UIP schedule?
No. UIP defines vaccines supplied through the national public programme, with some district- or campaign-specific elements. Professional private schedules can recommend additional vaccines or different products for individual benefit. Clinicians must state which framework they are using and avoid presenting private recommendations as universal government entitlement.
What changed nationally for HPV vaccination in India during 2026?
The Government launched nationwide free vaccination for eligible 14-year-old girls on 28 February 2026. The programme uses one dose of quadrivalent Gardasil-4 after consent at designated government facilities, with routine-day availability following the initial campaign. Previous HPV vaccination, pregnancy and specified clinical exclusions require reconciliation.
Can a child with a mild cold or malnutrition receive routine vaccines?
Mild illness and malnutrition are generally not reasons to lose an immunisation opportunity. Assess for moderate or severe acute illness and vaccine-specific contraindications, counsel the caregiver, and follow current programme guidance. Severe immunodeficiency, pregnancy for live vaccines, or prior component anaphylaxis requires product-specific expert review.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic